Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs TORM plc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while TORM plc trades at $40 (market cap $4.12B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 3.1× TORM plc's market cap, and TORM plc pays a 11.03% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and TORM plc for 23 Days on average.
| HALO | TRMD | |
|---|---|---|
Market Cap | $12.58B | $4.12B |
Volume | 2,179,278 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $115.22 | $41.05 |
52-Week Low | $61.63 | $19.39 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $14.49B | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TRMD trades at $39.94, up 2.62% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 35.52% net income margin and a low P/E of 6.59, indicating potential undervaluation. Recent earnings saw a mix of beats and misses, with Q3 2026 results pending. A $2.40 dividend is scheduled for payment in September 2026, and cash flow trends improved to a net positive in 2026.
The outlook is supported by robust fundamentals and a unanimous buy rating from analysts, but risks include volatile spot rates in the tanker market and recent insider selling. Revenue growth to $1.8B in 2026 underscores operational strength, yet dependence on freight rates poses a near-term headwind for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
